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Germline mutations of the LKB1 gene are responsible for
Peutz–Jeghers syndrome (PJS), an autosomal dominant
inherited disorder bestowing an increased risk of cancer.
We have recently demonstrated that LKB1 inactivating
mutations are not conﬁned to PJS, but also appear in lung
adenocarcinomas of sporadic origin, including primary
tumors and lung cancer cell lines. To accurately determine
the frequency of inactivating LKB1 gene mutations in lung
tumors we have sequenced the complete coding region of
LKB1 in 21 additional lung cancer cell lines. Here we
describe the mutational status of LKB1 gene in 30 lung
cancer cell lines from different histopathological types,
including 11 lung adenocarcinomas (LADs) and 11 small
cell lung cancers (SCLCs). LKB1 gene alterations were
present in six (54%) of the LAD cell lines tested but in
none of the other histological types. Similar to our
previous observations in primary tumors, all point
mutations were of the nonsense or frameshift type, leading
to an abnormal, truncated protein. Moreover, 2 cell lines
(A427 and H2126) harbored large gene deletions that
spanned several exons. Hence, we have identiﬁed addi-
tional lung cancer cell lines carrying inactivating muta-
tions of the LKB1 tumor suppressor gene, further
attesting to the signiﬁcance of this gene in the development
of LADs and providing new natural LKB1 knockouts for
studies of the biological function of the LKB1 protein.
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Introduction
LKB1, located on chromosome 19p, is the tumor
suppressor gene involved in the autosomal dominant,
cancer-predisposing disorder called Peutz–Jeghers syn-
drome (PJS) (Hemminki et al., 1998; Jenne et al., 1998).
Commonly, the LKB1 germline alterations detected in
patients with PJS generate premature truncated pro-
teins, either by nonsense or frameshift mutations in the
coding sequence or by partial or complete deletions of
the gene (Hemminki et al., 1998; Jenne et al., 1998). The
LKB1 protein is a serine/threonine kinase, and among
its biological substrates are PAR1 (Spicer et al., 2003),
which is required for establishing cell polarity during
embryogenesis, and AMPK (Hawley et al., 2003; Woods
et al., 2003), a key regulator of cellular metabolism. In
spite of its relevance in tumor development it is not yet
completely understood how LKB1 gene inactivation
contributes to tumor development. Recent reports
show that overexpression of LKB1 leads to cell
growth inhibition in certain cancer cells due to
p21-induced cell cycle arrest during G1 (Tiainen et al.,
1999), to growth arrest induced by the association with
Brg1 (a component of the chromatin remodeling
complexes) (Marignani et al., 2001), or to apoptosis
through its physical interaction with TP53 (Karuman
et al., 2001). Moreover, we have recently reported that
ectopic expression of LKB1 in deﬁcient cells leads to an
increase in the expression of several TP53-responsive
genes and of PTEN (Jimenez et al., 2003). Finally,
numerous proteins such as LIP1, STRADa and MO25a/
b have been reported to interact and regulate LKB1
activity (Smith et al., 2001; Baas et al., 2003; Boudeau
et al., 2003).
During the past decade, considerable effort has been
dedicated to the search for new tumor suppressor genes
in sporadic tumors. Genome-wide screening using LOH,
CGH and other approaches has identiﬁed several
chromosomal arms that are frequently lost in cancer.
However, in most cases, the targeted tumor suppressor
gene remains elusive (Sanchez-Cespedes, 2003). In lung
cancer, one of the most frequently deleted chromosomal
arms is the short arm of chromosome 19 (Virmani et al.,
1998; Sanchez-Cespedes et al., 2001). We have pre-
viously reported that LKB1 is the tumor suppressor gene
targeted in this region, because inactivating somatic
LKB1 gene mutations were present in one-third of
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sporadic lung adenocarcinomas (LADs) tested, includ-
ing 32 primary tumors and nine lung cancer cell lines
(Sanchez-Cespedes et al., 2002).
To determine the precise frequency of LKB1 gene
inactivation in lung tumors, avoiding the confounding
inﬂuence of normal cell contamination that often masks
the presence of partial deletions, and to identify possible
differences in the LKB1 mutation pattern among
distinct lung cancer histologies, we have now screened
21 additional lung cancer cell lines for LKB1 gene
alterations. We present data from the mutational
analysis in a panel of 30 lung carcinomas including 11
LADs, 11 small cell lung cancers (SCLCs) and others
(Table 1).
Our results revealed the presence of novel LKB1 gene
alterations in cell lines H1395, A427, H2126 and H460
Table 2 LKB1 gene alterations in lung adenocarcinoma cell lines.
Mutational data for KRAS and TP53 genes were obtained from the
NCI tumor cell line database (http://www.atcc.org/SearchCatalogs/
ncisearch.cfm) or by direct sequencing of PCR products using
standard protocols
Cell line Mutation type
(codon)
Predicted
product
Other
mutations
A427 Exons 1–5 Deletion, absence KRAS
A549a cag-tag (37) Gln to Stop KRAS
H460 cag-tag (37) Gln to Stop KRAS
H1395 ctgggggaa to
ctggggaa (56)
Deletion, frameshift BRAF1b
H23a tgg-tga (332) Trp to Stop TP53, KRAS
H2126 Exons 4–6 Deletion, absence TP53
aLKB1 mutations at these cell lines have previously been reported by
Sanchez-Cespedes et al., 2002. bBRAF1 mutation in the H1395 cells
has previously been reported by Davies et al., 2002
Figure 1 Genetic alterations of LKB1 in lung cancer cell lines. DNA from cell lines was extracted following standard protocols. To
screen for LKB1 gene mutations, we used 30–50 ng of genomic DNA for exon ampliﬁcation. Cycle sequencing reaction was performed
according to the manufacturer’s protocol (Perkin-Elmer, Roche Molecular Systems). Products were automatically sequenced in an ABI
PRISM 3700 DNA Analyser (PE Biosystems). Details of PCR conditions and primers used have been reported elsewhere (Sanchez-
Cespedes et al., 2002). (a) On the left, PCR products of indicated exons show absence of ampliﬁcation, indicating deletions at some
exons of the LKB1 gene in the A427 and the H2126 cell lines. Appropriate negative and positive (H69 cells) controls are also included.
The 1194-bp deletion in the H2126 cells can be observed on the right. (b) Electropherograms showing a 1-bp deletion in codon 56 at the
H1395 cells, a nonsense mutation at codon 37 (Gln-stop) at the H460 cells and the junction of the deletion at the H2126 cells. Normal
controls are also included
Table 1 Lung cancer cells lines tested for LKB1 gene alterations.
Asterisks indicate those cells that were screened in our previous report
(Sanchez-Cespedes et al., 2002)
SCLC NSCLC Others
LAD SCC Others
H69 A427 SK-MES-1 H661 H727
H82 A549* H226 H1155*
H187 Calu-3 H1299*
H209* H23* U1752
H345 H358* H1770*
H446 H441
H510 H460
H1618* H522*
N417 H1395
H249 H2087
H774 H2126
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(Table 2 and Figure 1). The H1395 cells carry a 1-bp
deletion in a stretch of guanines at codon 56 (exon 1);
the A427 cells have a partial deletion of the gene,
spanning from exons 1 to 5; the H460 cells have a C-to-
T mutation at codon 37, leading to a change from Gln
to a stop codon; the H2126 cells have a 1194-bp deletion
that abrogates exons 4–6. The latter observation was
conﬁrmed by RT–PCR, as shown in Figure 2. As can be
seen in Figure 1, all LKB1 gene alterations were
homozygous, indicating the loss of the remaining allele.
Intriguingly, the nonsense mutation at codon 37 in the
H460 cells is identical to that we previously reported for
the A549 cells and for a primary tumor (Sanchez-
Cespedes et al., 2002). We ruled out the possibility of
cross-contamination among cell lines because two
common germline polymorphisms at introns 1 and 3
were different in the A549 and H460 cells. A detailed
search of the mutational databases for LKB1 revealed
that this point mutation has never been reported in PJS
patients or in other sporadic tumors, implying that there
is a mutational hot spot in LADs. Among the LKB1
mutations closest to this putative hotspot reported to
date there is a somatic nonsense mutation at codon 36 in
a pancreatic tumor (Su et al., 1999) and a frameshift
mutation at codon 37 in a PJS family (Miyaki et al.,
2000). Mutational hot spots are fairly common in tumor
suppressor genes. It is well known that mutations at
guanine positions in codons 157, 248 and 273 at the
TP53 gene are hallmarks of lung tumorigenesis, which
has been associated with exposure to tobacco carcino-
gens (see Hainaut and Pfeifer, 2001 for review).
Overall, of the 11 LADs cell lines that we have tested
to date, six (54%) carry LKB1 gene alterations, all
predicting completely aberrant proteins (Table 2). Such
a high frequency is only comparable to the rates
reported for TP53 mutations, indicating that LKB1 is
among the most important tumor suppressor genes in
LADs. In our previous report (Sanchez-Cespedes et al.,
2002), LKB1 mutations were detected in one-third of
primary LADs. The slight discrepancy between the rates
of LKB1 gene inactivation in primary LADs and in lung
cancer cell lines probably implies that LKB1 gene
alteration frequencies are underestimated in primary
tumors. In DNA extracted from primary tumors, the
masking effect of contaminant normal cells that hinders
the detection of large deletions and complex gene
rearrangements is well known. Accordingly, the LKB1
gene deletions observed in the A427 and H2126 cell lines
would have remained undetected in a primary tumor.
Another deﬁnitive observation is the clustering of
LKB1 mutations in speciﬁc lung tumor histology.
Whereas half of the LADs carry LKB1 gene mutations,
none of the 11 SCLC cell lines evaluated in the present
study nor any of the 12 primary SCCs tested in our
previous work (Sanchez-Cespedes et al., 2002) revealed
LKB1 gene alterations. These observations are in
agreement with the signiﬁcantly decreased frequency of
LOH at chromosome 19p in SCLCs in comparison with
NSCLC (Virmani et al., 1998). Most of the malignant
tumors that arise in PJS patients are adenocarcinomas
(Giardiello et al., 1987), suggesting that LKB1 inactiva-
tion may be involved in the development of this speciﬁc
tumor histology. Since it is possible that other compo-
nents of the LKB1 biological pathway contribute to the
development of lung tumors devoid of LKB1 gene
alterations, increased effort should be made to elucidate
the biological function of LKB1 and to identify all
LKB1 substrates, since these are likely targets for gene
mutations.
Finally, we sought to identify a possible pattern of
LKB1 mutations linked to tobacco carcinogens. We
compared the eight nucleotide change mutations de-
scribed to date in sporadic LADs (Avizienyte et al.,
1999; Sanchez-Cespedes et al., 2002 and present work)
with the mutations in PJS patients (http://archive.
uwcm.ac.uk/uwcm/mg/search/9732383.html). Although
the number of LKB1 mutations in the sporadic lung
tumors is still too small to reach deﬁnitive conclusions,
no signiﬁcant differences were observed between the
two distinct populations of tumors. G-T or C-A
Figure 2 RT–PCR analysis of LKB1 mRNA in some of the lung
cancer cell lines. Total RNA was extracted following the
manufacturer’s instructions (RNeasy kit, Quiagen). A measure of
2mg of total RNA were reverse-transcribed with the Access RT
System (Promega) using random hexamers and 2 ml of produced
cDNA were ampliﬁed by standard protocols with speciﬁc primers
for the 1.2-kb fragment of the LKB1 cDNA. (a) RT–PCR of the
complete LKB1 transcript. The absence of RT–PCR product for
the A427 cells and a shorter product in the H2126 cells (398-bp
deletion) can be observed. (b) sequence of the cDNA indicating the
exact junction point between exons 4 and 7 that generates a
premature stop codon, as indicated. The wild-type sequence for the
H522 cells is also included as normal control
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transversions are more frequent in the p53 and KRAS
gene mutations that arise in sporadic lung tumors from
smokers as compared to nonsmoking-related tumors
(Ahrendt et al., 2001; Pfeifer et al., 2002). In our
analysis, 29 and 25% of the nucleotide changes at the
LKB1 gene were G-T/C-A transversions in sporadic
LADs and in tumors from PJS patients, respectively.
The frequency of C-T/G-A transitions was also
similar between the two groups, 50 and 35% in sporadic
LADs and in tumors from PJS patients, respectively.
To date, only a few cancer cell lines lacking wild-type
LKB1 protein have been reported: the melanoma cells
G361 (Tiainen et al., 1999), the cervical adenocarcinoma
cells HeLa S3 (Tiainen et al., 1999), and the lung
adenocarcinoma cells A549 and H23 (Sanchez-Cespedes
et al., 2002). Here, we report the presence of four
additional lung cancer cell lines carrying inactivating
LKB1 gene alterations, thus identifying new natural
‘knockout cell lines’ with distinct KRAS, and TP53
genetic background (Table 2). These observations
provide new tools for studies of the biological function
of the LKB1 protein. For example, recent evidence from
HeLa cells and from Lkb1-knockout mouse embryonic
ﬁbroblasts indicates that LKB1 is the upstream-activat-
ing kinase for the stress-responsive AMP-activated
kinase (AMPK) (Hawley et al., 2003). Our present
results identify new LKB1-deﬁcient cells that should
verify these observations in other tissues such as lung.
In conclusion, we have shown that LKB1 gene
inactivation is present in half of the LAD cells tested,
thereby demonstrating its relevance in the carcinogen-
esis of this tumor type and providing additional tools for
unraveling the biological function of LKB1.
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